文献速递功能神经外科

神经调控装置与疗法的自然史:以患者为中心的生存分析

Natural history of neuromodulation devices and therapies: a patient-centered survival analysis.
PubMed 文献 · J Neurosurg · 2019-04-19

该单中心回顾性研究用Kaplan-Meier法分析了1994—2015年450例DBS、383例VNS和128例SCS患者的装置与疗法生存。DBS和VNS的5年及10年装置生存率高于SCS,所有模态的疗法生存率均高于装置生存率,提示初次装置失效后仍可维持治疗获益。

要点

  • DBS的5年和10年装置生存率分别为87%和73%,疗法生存率分别为96%和91%。
  • VNS的5年和10年装置生存率分别为90%和70%,疗法生存率分别为99%和97%。
  • SCS的5年和10年装置生存率分别为50%和34%,疗法生存率分别为74%和56%。

核心结论

  • DBS和VNS的装置及疗法生存率均高于SCS。
  • 所有模态的疗法生存率均高于装置生存率,提示初次装置失效后仍可维持治疗获益。

研究设计与样本

  • 单中心回顾性分析1994—2015年接受DBS、VNS和SCS患者的装置与疗法生存数据,采用Kaplan-Meier生存分析。
  • 样本量:DBS 450例,VNS 383例,SCS 128例。

主要发现

  • DBS的5年和10年初始装置生存率分别为87%和73%,疗法生存率分别为96%和91%。
  • VNS的5年和10年初始装置生存率分别为90%和70%,疗法生存率分别为99%和97%。
  • SCS的5年和10年初始装置生存率分别为50%和34%,疗法生存率分别为74%和56%。
  • DBS、VNS和SCS的平均初始装置生存时间分别为14年、14年和8年,平均疗法生存时间分别为18年、18年和12.5年。
  • SCS患者硬件故障更常见,可能参与治疗中断。

临床怎么用

  • 向患者咨询时,应强调疗法生存率高于装置生存率,初次装置失效后仍可能维持治疗获益。
  • SCS的装置和疗法生存率较低,硬件故障更常见,需关注其治疗中断风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite rapid development and expansion of neuromodulation technologies, knowledge about device and/or therapy durability remains limited. The aim of this study was to evaluate the long-term rate of hardware and therapeutic failure of implanted devices for several neuromodulation therapies. METHODS: The authors performed a retrospective analysis of patients' device and therapy survival data (Kaplan-Meier survival analysis) for deep brain stimulation (DBS), vagus nerve stimulation (VNS), and spinal cord stimulation (SCS) at a single institution (years 1994-2015). RESULTS: During the study period, 450 patients underwent DBS, 383 VNS, and 128 SCS. For DBS, the 5- and 10-year initial device survival was 87% and 73%, respectively, and therapy survival was 96% and 91%, respectively. For VNS, the 5- and 10-year initial device survival was 90% and 70%, respectively, and therapy survival was 99% and 97%, respectively. For SCS, the 5- and 10-year initial device survival was 50% and 34%, respectively, and therapy survival was 74% and 56%, respectively. The average initial device survival for DBS, VNS, and SCS was 14 years, 14 years, and 8 years while mean therapy survival was 18 years, 18 years, and 12.5 years, respectively. CONCLUSIONS: The authors report, for the first time, comparative device and therapy survival rates out to 15 years for large cohorts of DBS, VNS, and SCS patients. Their results demonstrate higher device and therapy survival rates for DBS and VNS than for SCS. Hardware failures were more common among SCS patients, which may have played a role in the discontinuation of therapy. Higher therapy survival than device survival across all modalities indicates continued therapeutic benefit beyond initial device failures, which is important to emphasize when counseling patients.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Teton ZE, Blatt D, AlBakry A, et al. Natural history of neuromodulation devices and therapies: a patient-centered survival analysis. J Neurosurg. 2019. PMID: 31003217. doi:10.3171/2019.2.JNS182450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。